

2012 UK Cancer Diagnostics Market Outlook: Growth Opportunities and Strategies

<https://marketpublishers.com/r/FD85DEA2150EN.html>

Date: April 2012

Pages: 620

Price: US\$ 4,320.00 (Single User License)

ID: FD85DEA2150EN

Abstracts

This report presents a comprehensive analysis of the UK cancer diagnostics market, including:

Major issues pertaining to the UK laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years.

Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.

Ten-year test volume and sales forecasts for 40 cancer diagnostic procedures performed in UK hospitals and commercial laboratories.

Placements and installed base of automated and semiautomated analyzers used for cancer testing.

Current instrumentation technologies and feature comparison of leading analyzers.

Sales and market shares of leading suppliers.

Emerging diagnostic technologies and their potential market applications.

Product development opportunities.

Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

Business opportunities and strategic recommendations for suppliers.

Contains 620 pages and 85 tables.

Contents

INTRODUCTION

WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. CANCER STATISTICS AND ETIOLOGY

1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer

B. MAJOR CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS

1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembryonic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE

17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
 - ADA
 - B-Protein
 - PNP
 - 5'-Nucleotidase
27. Oncogenes
 - Abl/abl-bcr
 - AIB1
 - BCL-2
 - BRCA1
 - CD44
 - C-fos
 - C-myb
 - C-myc
 - CYP-17
 - Erb-B
 - HPC1
 - N-myc
 - P40
 - P51
 - P53
 - PIK3CA
 - PTI-1
 - Ras
 - Reg
 - Sis
 - Src
28. Polypeptide Growth Factors
 - Basic Fibroblast Growth Factor
 - Beta-TGF

Cachectin (TNT)
Calmodulin
ECFR
Nerve Growth Factor (NGF)
Epidermal Growth Factor (EGF)
Ornithine Decarboxylase
Transferrin
Transforming Growth Factor-Alpha

29. Ectopic Hormones

30. Colony Stimulating Factors

31. Lymphokines

Alpha-Interferon
B Cell Growth Factors
B Cell Growth Factor (BCGF)
Gamma-Interferon
Interleukin-1 (IL-1)
Macrophage Activating Factor

32. Immunohistochemical Stains

33. Emerging Tumor Markers

N-Acetylglucosamine
Actin
Alpha-Actin
Antineuronal Antibodies
7B2
B72.3
Bax
BCD-F9
BLCA-4
Blood Group Antigens A,B,H
CA 50
CA 72-4/TAG-72
CA 195
CA-242
CA-549
CAM 26
CAR-3
Cathepsin-D
Chromogranin A and B
Cluster 1 Antigen

Cluster-5/5A Antigen
CTA
CU18
DR-70
DU-PAN-2
Endometrial Bleeding Associated Factor
Endostatin
Epithelial Membrane Antigen
Feulgen Hydrolysis
Fibronectin
FSH
(1->3)-L-fucosyltransferase
Gastrin-Releasing Peptide (GRP)
GDCFP-15
Glucagon
Glycoamines
H23
Her-2
Human Carcinoma Antigen
HPA
HSP27
Intermediate Filaments
 Cytokeratins/CK18/Cyfra 21-1
 Desmin
 Gliofibrillary Acid Protein
 Neurofilaments
 Vimentin
KA 93
Kinases
KP16D3
LAI
Leukocyte Common Antigen
Lewis Antigens
Lysophosphatidic Acid (LPA)
Ma 695/Ma 552
MABDF3
MAG
ME1
Minactivin

MN/CA9
MSA
Mucin Cancer Antigen (MCA)
Multiple Tumor Suppressor 1
Myosin
NEA-130
NMP22
OA-519
Opioid Peptides
P-glycoprotein
Pancreatic Oncofetal Antigen (POA)
Placental Lactogen
PR92
Proliferative Index, Ki-67
Px
RB Inactivation/Deletion
Ret
SCCL 175
Selectin
Sialic Acid
Sialyl SSEA-1/SLX
SN10
Somatostatin
TA-90
TABA
Tachykinin
TAG 12
TPS
Troponin
Tubulin
VCAM
VEGF
Villen

C. INSTRUMENTATION REVIEW AND MARKET NEEDS

1. Abbott AxSYM
2. Abbott Architect c4000
3. Abbott Architect i2000 Series

4. Abbott Architect ci8200 System
5. Beckman Coulter UniCel Series
6. Beckman Coulter Access
7. Binding Site ESP600
8. bioMerieux Mini Vidas
9. Carolina Chemistries BioLis 24i
10. DiaSorin Liaison
11. Horiba ABX Pentra 400
12. Inverness DS2
13. J&J Vitros ECi/ECiQ
14. J&J Vitros 3600
15. J&J Vitros 5600
16. Olympus AU5400
17. Olympus AU3000i
18. Olympus AU2700
19. Roche Modular Analytics
20. Roche Cobas Integra 400
21. Roche Cobas Integra 400 Plus
22. Roche Elecsys
23. Roche Cobas c311
24. Siemens ADVIA Centaur
25. Siemens Dimension
26. Siemens Dimension RxL Max
27. Siemens Dimension Vista 500
28. Siemens Immulite
29. Siemens Stratus
30. Tosoh AIA-Series
31. Vital Diagnostics ATAC 8000
32. Vital Diagnostics Envoy 500

D. CURRENT AND EMERGING TECHNOLOGIES

1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
 - a. Technological Principle
 - b. Radioimmunoassay (RIA)
 - c. Enzyme Immunoassays (EIA)
 - Overview
 - ELISA

- Immunofiltration
- Particle-Membrane Capture Immunoassay
- Enzyme Amplification
- d. Fluorescent Immunoassays
- e. Luminescence
 - Chemiluminescence
 - Bioluminescence
- f. Latex Agglutination
- g. Immunoprecipitation
- h. Affinity Chromatography
- e. Liposome Flow-Injection Immunoassay
- 3. Molecular Diagnostics
 - a. Technology Overview
 - b. Amplification Methods
 - PCR
 - DAP-PCR
 - Immuno-PCR
 - QC-PCR
 - CAR
 - DNA
 - HPA
 - LCR
 - NASBA
 - QBR
 - SDA
 - 3 SR, and others
- 4. Chromosome Analysis
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas Lymphoid Malignancies
 - e. Chronic Lymphocytic Leukemia (CLL)
 - f. Solid Cancers
 - g. Chromosomal Translocation and Oncogenes
- 5. Artificial Intelligence
- 6. Flow Cytometry
- 7. Two Dimensional Gel Electrophoresis (2-DGE)
- 8. Biosensors
- 9. Competing/Complementing Technologies

- a. CT
- b. MRI
- c. NMR
- d. PET
- e. Photonics Spectroscopy

E. PERSONAL TESTING

U.K.

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth and Major Suppliers

MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
 - 1. Marketing Approaches
 - 2. Product Complexity
 - 3. Customer Preference
 - 4. Established Suppliers
 - 5. Emerging Suppliers
 - 6. Major Types of Distributors
 - 7. Market Segmentation Factor

POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

COMPETITIVE PROFILES

Abbott
AdnaGen
Applied Gene Technologies
Arca
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad
Cepheid
Correlogic Systems
Dako
Decode
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Enterix
Enzo Biochem
Epigenomics
Exact Sciences
Fujirebio
Gen-Probe
Guided Therapeutics
Hologic
Ipsogen
Kreatech
Kyowa Medex

Life Technologies
Mackay Life Sciences
Myriad Genetics
Nanogen Elitech
OncoLab
Otho-Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Veridex
Wako Pure Chemicals
Wallac/PE
Zila

APPENDIXES

Appendix I: Major Universities and Research Centers Developing Cancer Diagnostic Technology and Applications

Appendix II: Assumed Currency Exchange Rates

List Of Tables

LIST OF TABLES

Tumor Marker Classification

Major Companies Developing or Marketing ACTH Tests

Major Companies Developing or Marketing AFP Tests

Major Companies Developing or Marketing Beta-2 Microglobulin Tests

Major Companies Developing or Marketing CA 15-3/27.29 Tests

Major Companies Developing or Marketing CA 19-9 Tests

Major Companies Developing or Marketing CA 125 Tests

Major Companies Developing or Marketing Calcitonin Tests

Major Companies Developing or Marketing CEA Tests

Major Companies Developing or Marketing Estrogen Receptor Tests

Major Companies Developing or Marketing Progesterone Receptor Tests

Major Companies Developing or Marketing Ferritin Tests

Major Companies Developing or Marketing Gastrin Tests

Major Companies Developing or Marketing HCG Tests

Major Companies Developing or Marketing Insulin Tests

Major Companies Developing or Marketing NSE Tests

Major Companies Developing or Marketing Occult Blood Tests

Major Companies Developing or Marketing PAP Smear/HPV Tests

Major Companies Developing or Marketing PAP Tests

Major Companies Developing or Marketing PSA Tests

Major Companies Developing or Marketing Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications In Cancer Diagnosis

Oncogenes Potential Applications In Cancer Diagnosis

Major Companies Developing or Marketing Oncogene Tests

Growth Factors Potential Applications In Cancer Diagnosis

Colony Stimulating Factors Potential Applications in Cancer Diagnosis

Lymphokines Potential Applications In Cancer Diagnosis

Immunohistochemical Stains Potential Applications in Cancer Diagnosis

Executive Summary Table: U.K., Total Tumor Marker Test Volume and Sales Forecast
by Market Segment

U.K., Estimated Cancer Death Rates Per 100,000 Population

U.K., Laboratories Performing Tumor Marker Tests by Market Segment

U.K., Hospital Laboratories Performing Tumor Marker Tests by Bed Size

U.K., Commercial/Private Laboratories Performing Tumor Marker Tests by Annual Test
Volume

U.K., Total Tumor Marker Testing Volume Forecast by Market Segment
U.K., All Market Segments Major Tumor Marker Test Volume Forecast
U.K., Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
U.K., Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
U.K., Total Tumor Marker Sales Forecast by Market Segment
U.K., All Market Segments Major Tumor Marker Sales Forecast by Test
U.K., Hospital Laboratories Major Tumor Marker Sales Forecast by Test
U.K., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
U.K., ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., AFP Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., CEA Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Colon-Specific Antigen Test Volume And Diagnostics Sales by Market Segment
U.K., Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., HCG Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., NSE Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., PAP Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., PSA Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., S-100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., TDT Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., TPA Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Total Tumor Marker Sales and Market Shares Forecast

U.K., CEA Testing Market Diagnostics Sales by Major Supplier

U.K., PSA Testing Market Diagnostics Sales by Major Supplier

I would like to order

Product name: 2012 UK Cancer Diagnostics Market Outlook: Growth Opportunities and Strategies

Product link: <https://marketpublishers.com/r/FD85DEA2150EN.html>

Price: US\$ 4,320.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/FD85DEA2150EN.html>